NYXH Nyxoah SA IFRS
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1857190 · Reporting currency EUR · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY121.6%
TTM net income YoY-52.1%
TTM EPS YoY-30.7%
Revenue 3-yr CAGR48.1%
Net income 3-yr CAGR—
Margins
Gross margin63.1%
Operating margin-833.2%
Net margin-899.1%
FCF margin-696.4%
EBITDA margin—
Returns
ROE-111.0%
ROA-65.1%
ROIC (approx.)-134.3%
Asset turnover0.07x
Leverage & solvency
Liabilities / assets58.5%
Debt / equity0.00x
Current ratio1.25x
Interest coverage-7.25x
Cash quality & payout
Operating cash flow / net income0.77x
Accruals ratio-15.2%
Payout ratio—
Capex / revenue8.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: EUR | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | 10.02M | 4.52M |
| Cost of revenue | 3.69M | 1.55M |
| Gross profit | 6.33M | 2.97M |
| R&D expense | 42.82M | 34.33M |
| SG&A expense | 48.26M | 28.46M |
| Operating income | -83.48M | -58.81M |
| Interest expense | 11.52M | 5.07M |
| Pretax income | -89.08M | -56.43M |
| Income tax | 1.01M | 2.80M |
| Net income | -90.08M | -59.24M |
| EPS (basic) | -2.36 | -1.81 |
| EPS (diluted) | -2.36 | -1.81 |
| Balance sheet | ||
| Cash & equivalents | 30.00M | 34.19M |
| Receivables | 5.25M | 3.38M |
| Inventory | 4.66M | 4.72M |
| Current assets | 61.21M | 98.08M |
| PP&E, netmay include right-of-use assets (IFRS) | 4.05M | 4.75M |
| Intangibles | 50.11M | 50.38M |
| Total assets | 118.47M | 158.41M |
| Current liabilities | 48.96M | 21.53M |
| Total liabilities | 69.34M | 45.15M |
| Shareholders' equity | 49.13M | 113.25M |
| Shares outstanding | 43.03M | 37.43M |
| Cash flow statement | ||
| Operating cash flow | -68.98M | -49.23M |
| Capital expenditure | 805,000 | 1.17M |
| Free cash flow | -69.78M | -50.39M |
| Investing cash flow | 28.33M | -16.32M |
| Financing cash flow | 38.11M | 77.44M |
| Stock-based compensation | 4.89M | 3.97M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.